Dirk Bumann and Mattias Kassack are this year's Society for Biomolecular Screening Small Grants Award winners, SBS said recently.
Bumann, an independent research group leader at the Hannover Medical School in Germany, is studying Salmonella host-pathogen interactions using a FACS-based high-information content assay that simultaneously monitors several metabolic pathways in live Salmonella. Bumann holds a PhD from Max Planck Institute of Biochemistry, and conducted his postdoc at the Marine Biological Laboratory in Woods Hole, Mass.
Kassack's work involves the estimation of functional and binding properties of compounds at G-protein coupled receptors by flow cytometry. Kassack is currently a college lecturer and principal investigator at the University of Bonn Pharmaceutical Institute in Germany. He holds a PhD from the University of Bonn, and conducted his postdoc at the University of California, San Francisco.
Maurizio Grimaldi has joined Southern Research Institute to lead its drug-discovery team in efforts to develop new drugs for neurological and CNS disorders, SRI said recently.
Prior to joining SRI, Grimaldi conducted research at the National Institute for Neurological Disorders and Stroke, the National Institute for Child and Human Development, and the National Institute for Mental Health. From 2000 to 2004, he was an assistant professor of neurology for the University of Health Sciences in Bethesda, Md. He has also consulted for Amersham and the National Institute for Deafness and Communicative Disorders.
US Food and Drug Administration Commissioner Lester Crawford has appointed Steven Galson to be director of the FDA's Center for Drug Evaluation and Research, the agency said in a statement last week.
Galson, a rear admiral in the commissioned corps of the US Public Health Service, had most recently served as acting center director, and formerly served as deputy director since he joined the FDA in 2001. Galson holds a BS from Stony Brook University, an MD from the Mt. Sinai School of Medicine and an MPH from the Harvard School of Public Health.
Galson replaces Janet Woodcock as director of the CDER. Woodcock has been named deputy commissioner for operations and chief operating officer at the FDA, Crawford said.